Filing Details

Accession Number:
0001144204-18-009846
Form Type:
13D Filing
Publication Date:
2018-02-20 17:27:36
Filed By:
Schuler Jack W
Company:
Accelerate Diagnostics Inc (NASDAQ:AXDX)
Filing Date:
2018-02-20
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Jack W. Schuler 15,348,513 689,355 15,348,513 689,355 16,037,868 29.0%
Filing
 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

(Amendment No. 7)*

 

Accelerate Diagnostics, Inc.

 

(Name of Issuer)

 

Common Stock, $0.001 per share par value

 

(Title of Class of Securities)

 

00430H 102

 

(CUSIP Number)

 

Jack W. Schuler

c/o Accelerate Diagnostics, Inc.

3950 South Country Club, Suite 470

Tucson, Arizona 85714

(520) 365-3100

 

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

January 9, 2017

 

(Date of Event which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 
 

 

CUSIP No. 00430H 102
1

Names of Reporting Persons.

 

Jack W. Schuler

2

Check the Appropriate Box if a Member of a Group

(a) ¨

(b) ¨

3

SEC Use Only

 

 

4

Source of Funds

 

PF

5

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

¨

6

Citizenship or Place of Organization

 

USA

NUMBER
OF SHARES
BENEFICIALLY
OWNED
BY EACH
REPORTING
PERSON

WITH
7

Sole Voting Power

 

15,348,513

8

Shared Voting Power

 

689,355

9

Sole Dispositive Power

 

15,348,513

10

Shared Dispositive Power

 

689,355

11

Aggregate Amount Beneficially Owned by Each Reporting Person

 

16,037,868

12

Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

¨

13

Percent of Class Represented by Amount in Row (11)

 

29.0%

14

Type of Reporting Person

 

IN

 

 

 

This Amendment No. 7 amends and supplements that certain Statement on Schedule 13D filed on May 3, 2012 by Abeja Ventures, LLC (“Abeja”), as amended by that certain Amendment No. 1 filed on July 9, 2012 by Abeja, Jack W. Schuler (“Mr. Schuler”), John Patience and Lawrence Mehren, as amended by that certain Amendment No. 1 filed on March 20, 2013 by Mr. Schuler, as amended by that certain Amendment No. 2 filed on July 10, 2013 by Mr. Schuler, as amended by that certain Amendment No. 3 filed on March 19, 2014 by Mr. Schuler, as amended by that certain Amendment No. 4 filed on May 28, 2014 by Mr. Schuler, as amended by that certain Amendment No. 5 filed on December 29, 2015 by Mr. Schuler, as amended by that certain Amendment No. 6 filed on February 25, 2016 (collectively, the “Schedule 13D”), with respect to the common stock, $0.001 per share par value (the “Common Stock”), of Accelerate Diagnostics, Inc., a Delaware corporation formerly known as Accelr8 Technology Corporation (the “Company”). This Amendment is being filed to report transactions that should have been reported in amendments to the Schedule 13D since the filing of the last amendment on February 9, 2016 (the “2016 Amendment”). It further updates the beneficial ownership of Mr. Schuler subsequent to the date of the 2016 Amendment through the date hereof.

 

Capitalized terms used herein and not otherwise defined in this Amendment No. 7 shall have the meanings set forth in the Schedule 13D. Except as specifically set forth herein, the Schedule 13D remains unmodified.

 

Item 5. Interest in Securities of Issuer

 

Items 5(a) and 5(c) of the Schedule 13D are amended and restated as follows:

 

(a)           Based on information provided by the Company to Mr. Schuler, the percentage of shares owned is based upon 55,397,563 shares of Common Stock issued and outstanding as of November 7, 2017. Mr. Schuler beneficially owns 16,037,868 shares of Common Stock, representing 29.0% of the issued and outstanding Common Stock. The shares beneficially owned by Mr. Schuler include 13,125,028 shares held by the Jack W. Schuler Living Trust (Mr. Schuler has sole and dispositive power with respect to such shares in his capacity as trustee of the trust); 1,500,323 shares held by the Schuler Family Foundation (Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as President of the entity); 689,355 shares held by Schuler Grandchildren LLC (Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as manager of the entity); 689,355 shares held by Schuler GC 2010 Continuation Trust (Mr. Schuler has shared voting and dispositive power with respect to such shares in his capacity as the grantor of the trust); and 33,807 shares issuable to Mr. Schuler individually in respect of stock options exercisable within 60 days of the date of this filing. Mr. Schuler disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

 

 

 

(c)           The following table sets forth all transactions in the Company’s Common Stock effected by Mr. Schuler (indirectly) during the 60 days prior to the date of this Amendment No. 7 and prior to the date of each amendment that should have been filed since the date of the 2016 Amendment. All such transactions were purchases of Common Stock on the open market, except as noted below.

 

Date of Transaction Name of Party Effecting Transaction Number of Common Stock Average Price Per Share
1/9/2017 Jack W. Schuler Living Trust 211,000 $19.00
1/9/2017 Schuler Family Foundation 128,368 $19.00
8/21/2017 Jack W. Schuler Living Trust 37,270 $21.34
8/21/2017 Jack W. Schuler Living Trust 12,730 $21.76
10/11/2017 Jack W. Schuler Living Trust 51,600 $20.27
10/12/2017 Jack W. Schuler Living Trust 276,200 $19.74
10/13/2017 Jack W. Schuler Living Trust 29,240 $18.81
10/13/2017 Jack W. Schuler Living Trust 32,060 $19.72
10/16/2017 Jack W. Schuler Living Trust 59,922 $20.07
10/17/2017 Jack W. Schuler Living Trust 13,250 $20.29
10/18/2017 Jack W. Schuler Living Trust 45,000 $20.14
11/6/2017 Schuler Family Foundation 340,864 $18.51
11/6/2017 Schuler Family Foundation 100 $19.00
11/7/2017 Schuler Family Foundation 50,000 $18.73
11/8/2017 Schuler Family Foundation 50,000 $18.46
11/9/2017 Schuler Family Foundation 26,600 $18.54
11/10/2017 Schuler Family Foundation 24,581 $18.81
11/13/2017 Schuler Family Foundation 20,000 $18.98

 

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

 

 

Date: February 20, 2018 By: /s/ Jack W. Schuler  
    Jack W. Schuler